Western Regional Blog – BC, YK, AB, NWT and Nunavut
‘A new biomarker predicts PARP response in ovarian cancer’ was released by MedScape today.
Read the MedScape article here.
A novel biomarker has been identified that can predict which women with ovarian cancer will respond to PARP inhibitors over and above the women with BCRA1 and BCRA2 mutations who are known responders to this drug class, new research shows.
The study was presented at the 26th EORTSC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
“This is the first time that we have predictors to identify women with ovarian cancer other than those with a known BRCA1 or BRCA2 mutation who are likely to respond to a PARP inhibitor,” Elizabeth Swisher, MD, University of Washington School of Medicine, Seattle, said in a statement.
“And this will allow more focused application of PARP inhibitors to women most likely to benefit from treatment with them,” she added.
The new data come from the ARIEL2 study (Assessment of Rucaparib in Ovarian Cancer trial), a phase 2 clinical trial in which women with previously treated advanced ovarian cancer are receiving the investigational PARP inhibitor rucaparib (Clovis Oncology) at a dose of 600 mg twice daily, until disease progression.